Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade

por Hennigs, A., Riedel, F., Marmé, F., Sinn, P., Lindel, K., Gondos, A., Smetanay, K., Golatta, M., Sohn, C., Schuetz, F., Heil, J., Schneeweiss, A.
Publicado 2016

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer

por Hohaus, S, Funk, L, Martin, S, Schlenk, R F, Abdallah, A, Hahn, U, Egerer, G, Goldschmidt, H, Schneeweiß, A, Fersis, N, Kaul, S, Wallwiener, D, Bastert, G, Haas, R
Publicado 1999

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change...

por Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.
Publicado 2013

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or meta...

por Emens, L.A., Adams, S., Barrios, C.H., Dieras, V.C., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Chui, S.Y., Schmid, P.
Publicado 2020

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from t...

por Yardley, D A, Coleman, R, Conte, P, Cortes, J, Brufsky, A, Shtivelband, M, Young, R, Bengala, C, Ali, H, Eakel, J, Schneeweiss, A, de la Cruz-Merino, L, Wilks, S, O’Shaughnessy, J, Glück, S, Li, H, Miller, J, Barton, D, Harbeck, N
Publicado 2018

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

por Müller, V., Banys-Paluchowski, M., Friedl, T.W.P., Fasching, P.A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T.
Publicado 2021

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

por Jaeger, B. A. S., Neugebauer, J., Andergassen, U., Melcher, C., Schochter, F., Mouarrawy, D., Ziemendorff, G., Clemens, M., v. Abel, E., Heinrich, G., Schueller, K., Schneeweiss, A., Fasching, P., Beckmann, M. W., Scholz, Ch., Friedl, T. W. P., Friese, K., Pantel, K., Fehm, T., Janni, W., Rack, B.
Publicado 2017

COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

por Pixberg, C., Zapatka, M., Hlevnjak, M., Benedetto, S., Suppelna, J.P., Heil, J., Smetanay, K., Michel, L., Fremd, C., Körber, V., Rübsam, M., Buschhorn, L., Heublein, S., Schäfgen, B., Golatta, M., Gomez, C., von Au, A., Wallwiener, M., Wolf, S., Dikow, N., Schaaf, C., Gutjahr, E., Allgäuer, M., Stenzinger, A., Pfütze, K., Kirsten, R., Hübschmann, D., Sinn, H.-P., Jäger, D., Trumpp, A., Schlenk, R., Höfer, T., Thewes, V., Schneeweiss, A., Lichter, P.
Publicado 2022